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During the last decade, the emerging ﬁeld of molecular ﬂuorescence imaging has led to the
development of tumor-speciﬁc ﬂuorescent tracers and an increase in early-phase clinical
trials without having consensus on a standard methodology for evaluating an optical tracer.
By combining multiple complementary state-of-the-art clinical optical imaging techniques, we
propose a novel analytical framework for the clinical translation and evaluation of tumor-
targeted ﬂuorescent tracers for molecular ﬂuorescence imaging which can be used for a
range of tumor types and with different optical tracers. Here we report the implementation of
this analytical framework and demonstrate the tumor-speciﬁc targeting of escalating doses of
the near-infrared ﬂuorescent tracer bevacizumab-800CW on a macroscopic and microscopic
level. We subsequently demonstrate an 88% increase in the intraoperative detection rate of
tumor-involved margins in primary breast cancer patients, indicating the clinical feasibility
and support of future studies to evaluate the deﬁnitive clinical impact of ﬂuorescence-guided
surgery.
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Molecular ﬂuorescence imaging enables visualization oftumor-speciﬁc, upregulated proteins and biologicalprocesses involved in oncogenesis and allows real-time
imaging of tumor tissue with a high resolution for various clinical
applications, such as image-guided surgery, endoscopy, and
pathology. During the past decade, several tumor-speciﬁc ﬂuor-
escent tracers have been developed and validated in animal
models, leading more recently to a substantial increase in early-
phase clinical trials evaluating molecular ﬂuorescence imaging1,2.
Despite the increasing activity in the ﬁeld, several critical factors
to ensure translation of optical tracers to clinical applications
remain insufﬁciently established. No widely accepted analytical
framework or standard evaluation methodology serves as a gold
standard for determining the efﬁcacy of a ﬂuorescent tracer in
clinical applications.
The majority of these early-phase clinical studies have been
executed in image-guided surgery applications. In oncological
surgery, it is important to remove the tumor completely without
any residual disease, since incomplete resections are inevitably
associated with higher rates of re-operations, increased rates of
recurrent disease and lower overall survival3. Intraoperatively,
surgeons are mainly dependent on visual inspection and palpa-
tion alone to distinguish cancer tissue from benign tissue, a
method with unknown accuracy. The available intraoperative
techniques for margin assessment have not yet been adopted
universally. Frozen section analysis and imaging techniques like
specimen radiography are time consuming and lack diagnostic
accuracy4. Anatomical imaging modalities like CT and MRI have
been adapted for use in the operating theatre, but cannot be used
in real-time and have limited tumor speciﬁcity. Consequently,
there is an unmet need for real-time tumor-speciﬁc imaging that
is compatible with the workﬂow in the operating theatre. This
might be provided by using sensitive optical imaging techniques
combined with tumor-speciﬁc ﬂuorescent tracers; this approach
is currently under investigation in early-phase clinical trials1.
As there is no consensus on a standard evaluation methodol-
ogy for ﬂuorescence imaging, we implemented a novel analytical
framework for data collection, and ﬂuorescence image analyses
based on our experience in molecular ﬂuorescence imaging in
surgery and endoscopy5–8. In the present study we implement
this novel analytical framework and conﬁrm the tumor-speciﬁc
targeting of the near-infrared (NIR) ﬂuorescent tracer
bevacizumab-800CW in escalating doses on a macroscopic and a
microscopic level. We subsequently observed an 88% increase in
the intraoperative detection of tumor-involved margins, thus
indicating clinical feasibility in support of future studies to eval-
uate the deﬁnitive clinical impact of ﬂuorescence-guided surgery
in primary breast cancer patients.
Results
Summary of study design and patient demographics. The study
was designed as a clinical dose escalation trial investigating four
doses of bevacizumab-800CW (4.5 mg, 10 mg, 25 mg, and 50 mg)
in patients with invasive T1–T2 primary breast cancer scheduled
for breast cancer surgery. Bevacizumab-800CW was injected
intravenously three days prior to surgery (Fig. 1a). A step-up
approach was used in which three patients per dose group were
included, followed by expansion of the two best-performing dose
groups to a total of ten patients each (Supplementary Fig. 1).
Twenty-six patients with invasive primary breast cancer were
enrolled between 12 October 2015 and 2 February 2017. Three
patients received 4.5 mg, ten patients 10 mg, ten patients 25 mg,
and three patients 50 mg of bevacizumab-800CW. No serious
adverse events, allergic or anaphylactic reactions, were reported in
this trial. Two adverse events were reported, one patient from the
4.5 mg group experienced nausea till 30 min after tracer injection,
another patient from the 25 mg group had hot ﬂushes after tracer
administration that recovered spontaneously. None of the
patients felt any burden of the infusion three days prior to
surgery.
In 19 patients, histopathological analyses showed an invasive
carcinoma of no special type (NST); in ﬁve patients a lobular
carcinoma, in one patient a mucinous carcinoma and in one
patient a papillary carcinoma. In four patients, there was a tumor-
involved surgical margin of the invasive primary tumor; in four
other patients the surgical margin of unexpected additional
carcinoma in situ was positive adjacent to a completely removed
primary tumor. This resulted in a total positive-margin rate of
30% according to the most recent SSO-ASTRO guidelines9
(Table 1).
800 CW Hoechst 480 nm
FFPE block
h
10-µm-thick section
j
Fresh specimen
d l
4-µm-thick section
b
Intraoperative
f
Fresh tissue slice
3 
da
ys
Tracer injectiona
High
Low
Intraoperative imaging
potential clinical impact
Specimen imaging
potential clinical impact
Macro-segmentation
tumor-to-background ratio
Micro-segmentation
biodistribution
Safety
Serially
slicing
Paraffin
embedding
Fluorescence microscopy
cellular distribution
Macroscopic imaging Microscopic imaging
25 µm
i ke
m
gc
25 µm
Fig. 1 The clinical analytical framework enabling correlation of intraoperative ﬂuorescence signals with histopathology, from macroscopic to microscopic
levels. a Intravenous administration of bevacizumab-800CW three days prior to surgery. b, c Color image and corresponding ﬂuorescence image obtained
in vivo during surgery to determine potential clinical value. d, e Imaging of the fresh surgical specimen, followed by serially slicing. f, g Imaging of the fresh
tissue slices to determine tumor-to-background ratio based on macro-segmentation, followed by parafﬁn embedding. h, i Imaging of formalin-ﬁxed
parafﬁn-embedded (FFPE) blocks to determine heterogeneity of tracer uptake within a tumor. j, k Imaging of 10-µm-thick tissue sections for micro-
segmentation to reveal microscopic biodistribution and correlation with ﬂuorescence signals from the macroscopic to microscopic level. l, m Fluorescence
microscopy to determine tracer distribution on a cellular level. Scale bars represent 1 cm, in l, m the scale bar represents 25 µm
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The analytical framework. Breast-conserving surgery consists of
intraoperative assessment of the margins by the surgeon using
visual inspection and palpation and evaluation of the excised
specimen by standard histopathology. Therefore, the data collec-
tion procedure within the analytical framework to determine the
tumor-speciﬁc targeting of bevacizumab-800CW should ﬁt the
standard workﬂow and needs to provide qualitative and quanti-
tative data on ﬂuorescence related to the standard of care. As such,
the data collection procedure within the analytical framework
consisted of: (i) qualitative in vivo intraoperative macroscopic
imaging to determine the potential clinical value of ﬂuorescence-
guided surgery (Fig. 1b, c), (ii) qualitative ex vivo imaging of the
fresh whole surgical specimens (Fig. 1d, e), (iii) quantitative
ex vivo imaging of the fresh tissue slices of the fresh specimens to
determine the tracer distribution on a macroscopic level (Fig. 1f,
g), (iv) quantitative multi-diameter single-ﬁber reﬂectance/single-
ﬁber ﬂuorescence (MDSFR/SFF) spectroscopy of the fresh tissue
slices to determine the intrinsic ﬂuorescence intensities, (v)
quantitative ﬂuorescence ﬂatbed scanning of formalin-ﬁxed par-
afﬁn-embedded (FFPE) blocks and 10-µm-thick sections to
determine the tracer distribution on a microscopic level
(Fig. 1h–k), and (vi) ﬂuorescence microscopy (Fig. 1l, m).
Quantitative macro-segmentation of the fresh tissue slices. In
all patients, qualitative assessment of ﬂuorescence signals showed
higher ﬂuorescence signal intensities in tumor tissue compared to
normal surrounding tissue at all ex vivo imaging modalities,
including the fresh tissue slices, FFPE blocks and 10-µm-thick
sections. Representative images per dose group and per imaging
modality are shown in Fig. 2a–x. A complete overview per patient
is shown in Supplementary Fig. 2. Sodium dodecyl sulfate poly-
acrylamidegel electrophoresis (SDS-PAGE) of tumor lysates
demonstrated that the complete compound bevacizumab-800CW
was intact and present in the human primary breast tumor, as
conﬁrmed by comparing the height of the band of the tumor
lysates with the lane containing diluted bevacizumab-800CW
(Supplementary Fig. 3).
We used ﬂuorescence images of all fresh tissue slices obtained
by a light-tight macroscopic imaging device for quantitative
macro-segmentation analyses to determine the tumor-speciﬁc
targeting of bevacizumab-800CW on a macroscopic level by
calculating the tumor-to-background ratio (TBR). Freshly excised
tissue represents the in vivo situation the best for the calculation
of the TBR, as it has not yet been processed with formalin or
embedded in parafﬁn and the conditions of imaging are the most
optimally standardized; i.e., the tumors within the slices are all on
the surface without overlaying tissue, the distance from stage to
camera is equal in all patients, and no ambient light is inﬂuencing
the ﬂuorescent signals. In the ﬂuorescence images of all fresh
tissue slices that contained tumor tissue after conﬁrmation with
histology, regions-of-interests of tumor tissue, as well as back-
ground tissue were manually segmented. The mean ﬂuorescence
intensity (MFI) was measured per region-of-interest (ROI) and
averaged per tissue type, resulting in an MFI of tumor tissue and
an MFI of background tissue per patient. TBR was calculated as
the ratio of MFI of tumor compared to the MFI of normal tissue.
Macro-segmentation analyses were performed on a total of 69
fresh tissue slices from 23 patients. In three patients, the light-
Table 1 Demographics of study patients
4.5 mg 10mg 25mg 50mg
n= 3 n= 10 n= 10 n= 3
Patient characteristics
Age (years/range) 72 (68–77) 61 (50–69) 57 (49–69) 63 (53–70)
Clinicopathological parameters (number)
Tumor type invasive primary tumor
Invasive carcinoma of no speciﬁc type 2 9 6 2
Lobular caricnoma 0 1 4 0
Mucinous carcinoma 0 0 0 1
Papillary carcinoma 1 0 0 0
Tumor size (cm/range) 1.5 (1.4–1.7) 1.3 (0.5–2.4) 1.8 (0.7–3.2) 0.9 (0.8–1.1)
Tumor grade (modiﬁed Bloom-Richardson)
Grade I 0 4 0 0
Grade II 3 4 7 0
Grade III 0 2 3 2
n/a — — — 1
Estrogen receptor positive (>10%) 3 9 8 3
Progesterone receptor positive (>10%) 2 8 7 2
HER2 receptor positive
(IHC 2+ or 3+with positive FISH) 1 1 1 1
Carcinoma in situ present 1 6 9 3
Safety data (number)
Adverse events 1 0 1 0
Serious adverse events 0 0 0 0
Surgical resection margin status (number)a
Primary tumor
Free 3 7 9 3
Not free 0 3 1 0
Additional Carcinoma in situ component
Free 1 5 7 2
Not free 0 1 2 1
a Denotes according to ASTRO guidelines
HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, FISH ﬂuorescence in situ hybridization
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tight macroscopic ﬂuorescence imaging device malfunctioned;
these patients were excluded. Quantitative macro-segmentation
analyses conﬁrmed signiﬁcantly higher ﬂuorescence signals in
tumor tissue relative to normal background tissue in the 10 and
25 mg dose groups (Fig. 2-I). The MFI of tumor tissue increased
from a median of 5368 in the 4.5 mg group to a median of 18,472
in the 50 mg group (Fig. 2-I). The 25 mg dose group showed a
signiﬁcantly higher MFI in tumor tissue compared to tumor
tissue in the 10 mg dose group (median MFI 25 mg= 14,390,
median MFI 10 mg= 6014; P= 0.0297, Kruskal–Wallis test). No
increase in MFI of normal background tissue was observed
between the 10 and 25 mg dose groups (P= 0.0880,
Kruskal–Wallis test), resulting in a signiﬁcantly higher TBR of
3.07 in 25 mg group patients versus 1.79 in 10 mg group patients
(P= 0.0097, Kruskal–Wallis test)(Fig. 2-III).
MDSFR/SFF spectroscopy. MDSFR/SFF spectroscopy was per-
formed on the fresh tissue slices in order to quantify the intrinsic
ﬂuorescence by correcting the ﬂuorescence signal for the tissue
optical properties scattering and absorption. Per patient three
spots in the same fresh tissue slice were measured of both tumor
tissue and normal tissue, per spot three measurements were done.
In the 13 patients with available MDSFR/SFF data, intrinsic
ﬂuorescence in tumor tissue was signiﬁcantly higher compared to
normal tissue in the 10 mg dose group (P= 0.0022,
Mann–Whitney U-test) and the 25 mg dose group (P= 0.0159
Mann–Whitney U-test) (Fig. 2-II). Furthermore, a larger varia-
tion of ﬂuorescence intensity between patients was observed in
the 25 and 50 mg groups. When comparing results of MDSFR/
SFF spectroscopy with macro-segmentation of the fresh tissue
slices, a similar trend of increasing ﬂuorescence levels in tumor
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Fig. 2 Representative images per dose group and per optical imaging method for ex vivo analyses, including MDSFR/SFF spectroscopy. Columns represent
the four dose groups: 4.5 mg (a–f), 10 mg (g–l), 25 mg (m–r), 50mg (s–x). Rows represent the imaging modality, in the upper part a white light image and
in the lower part the representative ﬂuorescence image. Tumor tissue is delineated with a dashed line. Scale bars represent 1 cm. I Mean ﬂuorescence
intensity (MFI) of normal tissue (gray) and tumor tissue (black) are depicted per dose group on the left y-axis, the right y-axis shows the tumor-to-
background ratio per patient per dose group for macro-segmentation analyses, in II for MDSFR/SFF spectroscopy measurements and in III for micro-
segmentation analyses. Fluorescence images are scaled using the most optimal minimum and maximum displayed value. Boxplot centerline is at median,
the bounds of the box at 25th to 75th percentiles, the whiskers are depicting the min–max, tumor-to-background ratio data are depicted per patient; line
indicates median value per dose group. Asterisk denotes signiﬁcant (P < 0.05, Kruskal–Wallis test) values. Obelisk denotes signiﬁcant (P < 0.05,
Mann–Whitney U-test) values. FFPE formalin-ﬁxed, parafﬁn embedded, MDSFR/SFF multi-diameter single-ﬁber reﬂectance/single-ﬁber ﬂuorescence.
Q.μfa,x the product of the quantum efﬁciency across the emission spectrum, Q[-], where Q is the ﬂuorescence quantum yield of IRDye-800CW and
μaf [mm−1] is the tracer absorption coefﬁcient at the excitation wavelength
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tissue with escalating tracer doses was observed, whereas no
difference in ﬂuorescence levels was measured in background
normal breast tissue between the dose groups.
Quantitative micro-segmentation of 10-µm-thick FFPE sec-
tions. To assess the detailed microscopic biodistribution of
bevacizumab-800CW in human breast tissue, we performed
micro-segmentation on a total of 200 10-µm-thick FFPE sections
(Fig. 3a–l). In all 26 patients, tumor tissue showed a higher MFI
compared to the entire normal breast tissue. Normal tissue was
deﬁned as fat and parenchymal breast tissue including collagen
(Fig. 2-III, Fig. 3m). When analyzing the MFI per tissue type per
dose group, we observed an increase in MFI for all tissue types.
However, a higher tracer uptake in tumor tissue remains in
escalating doses, which indicates tumor-speciﬁc targeting of the
tracer irrespective of dosing (Fig. 4e–i). To visualize the differ-
ences in tumor tissue and normal parenchyma, we plotted the
tumor-to-parenchyma ratio, per patient and per dose group
(median per dose group is indicated with a horizontal line). In
ﬁve patients, the tumor-to-parenchyma ratio was below 1, what
means that the tumor MFI was lower than the MFI of the par-
enchyma tissue (Fig. 4j).
Potential clinical value of ﬂuorescence-guided surgery. Since
macro-segmentation analyses and micro-segmentation analyses
conﬁrmed tumor-speciﬁc targeting of bevacizumab-800CW
irrespective of the dosing, we evaluated the potential clinical
value of molecular-ﬂuorescence-guided surgery in breast cancer
patients. We qualitatively analyzed the intraoperative ﬂuores-
cence image and video data in combination with the ﬂuorescence
images of the freshly excised specimen. Intraoperative imaging
took place at two time points during surgery; the tumor was
imaged just before excision and the surgical cavity was imaged
directly after removal of the tumor. Since this clinical trial was not
designed to alter the standard of care, surgeons were not allowed
to excise additional tissue based on intraoperatively detected
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ﬂuorescence signals. Therefore, intraoperative ﬁndings could only
be retrospectively correlated with histopathology. Representative
examples of ﬂuorescence images from a patient with a tumor-
involved surgical margin, and from a patient with a tumor-free
surgical margin are presented in Fig. 5. We observed in the
ﬂuorescence scan of the 10 µm slide also non-fatty is lit up by the
ﬂuorescent tracer (Fig. 5t). We further investigated the possible
cause of this high uptake by sectioning the tissue FFPE block
several slides deeper, and strikingly, in these deeper sections we
found tumor tissue present at the site where the high uptake is
visible in the original slide (Fig. 5v). It is known that VEGF is
present is in the microenvironment of the tumor10. Probably, the
VEGF expressed in the non-fatty tissue is a ﬁeld-effect from
secretion from deeper seated underlying tumor cells which might
explain the high bevacizumab-800CW uptake.
In eight of the 26 patients (31%) a tumor-involved surgical
margin was reported after histopathological analyses; using
current clinical surgical practice, none of these margins were
detected intraoperatively (Table 2). When using ﬂuorescence, in
seven of these eight patients (88%) a clear ﬂuorescence signal was
detected in the surgical cavity by intraoperative ﬂuorescence
imaging, suggesting a tumor-positive resection margin. In three of
those seven patients, the primary tumor was not completely
resected, whereas in four other patients the surgical margin
contained additional carcinoma in situ components next to a
completely resected primary tumor. In one patient, in which
histopathological analysis showed ink on the invasive primary
tumor, no ﬂuorescence signal was detected in the surgical cavity.
In contrast to the intraoperative imaging of this patient, ex vivo
analyses of the fresh tissue slices showed clear uptake of the tracer
in the tumor tissue, and also a close surgical margin was
suspected on the ﬂuorescence images of the fresh tissue slices
(Supplementary Fig. 2b).
In 18/26 patients (69%) a tumor-free surgical margin was
reported after histopathological analyses (Table 2). In 16 of these
18 patients (89%) no intraoperative signals were detected in the
surgical cavity, whereas in the two remaining patients with a
tumor-free surgical margin (2/26, 7.6%), a positive ﬂuorescence
cavity signal was detected. In these two patients, high ﬂuorescence
signals were observed in surrounding healthy tissue containing
abundant collagen, normal parenchyma, accompanied by ade-
nosis and a periductular plasma cell inﬁltrate as detected in
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micro-segmentation analyses, which could explain these ﬁndings
(Supplementary Fig. 2d).
Discussion
In the emerging ﬁeld of molecular ﬂuorescence imaging a robust
and broadly applicable analytical framework for clinical transla-
tion of ﬂuorescent tracers is lacking. Based on our experience in
the ﬁrst clinical trials investigating ﬂuorescence-guided surgery in
human, we propose a standard evaluation methodology for
clinical translation of ﬂuorescent tracers by combining com-
plementary qualitative and quantitative clinical optical imaging
techniques5–8.
Earlier, we demonstrated that a microdose of bevacizumab-
800CW speciﬁcally targets vascular endothelial growth factor A
(VEGF-A) in patients with primary breast cancer7. VEGF-A is
present in all breast cancer types11–14, as it is a generic target
upregulated in many solid tumors and regarded one of the hall-
marks of cancer15. Besides, we have demonstrated earlier that the
antibody bevacizumab still has intact afﬁnity for the target after
conjugation with IRDye-800CW and the labeling procedure does
not inﬂuence the structural integrity and post translational
modiﬁcations of bevacizumab not leading to an affected mode of
action by the IRDye-800CW conjugation16. Data derived from
preclinical studies conﬁrm that Bevacizumab-800CW has a
comparable biodistribution as 89Zr-Bevacizumab17.
By implementing our novel analytical framework for the ﬁrst
time in the current study, we conﬁrmed the tumor-speciﬁc tar-
geting of bevacizumab-800CW in escalating doses by tracing
down bevacizumab-800CW on both a macroscopic and micro-
scopic level within the individual components of the proposed
analytical framework. Because we demonstrated the tumor-
speciﬁc targeting of bevacizumab-800CW irrespective of dosing,
we subsequently showed the potential clinical value of
ﬂuorescence-guided surgery in breast cancer patients, indicating
the clinical feasibility and support of future studies to evaluate the
deﬁnitive clinical impact of ﬂuorescence-guided surgery in pri-
mary breast cancer patients. Using ﬂuorescence-guided surgery in
primary breast cancer patients, we showed that the intraoperative
detection of tumor-involved margins is much better than stan-
dard surgical practice, this was conﬁrmed by ex vivo analyses
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Fig. 5 Representative examples of intraoperatively detected tumor-involved surgical margin and a tumor negative surgical margin. Columns represent from
left to right intraoperative imaging, fresh specimen imaging, fresh tissue slice imaging, FFPE block imaging, and imaging of 10-µm-thick sections. The two
upper rows represent a patient with a tumor-positive surgical margin, a clear ﬂuorescence signal was detected in the surgical cavity. Subsequently, the
corresponding resection plane of the excised specimen was marked with an extra suture (a, b). Fluorescence imaging of the fresh surgical specimen
showed high ﬂuorescence signals at the area of the suture mark (c, d, asterisk). Corresponding ﬂuorescence images of fresh tissue slices, FFPE blocks and
10-µm-thick sections showed high ﬂuorescence signals at the margin (e–j, arrows). Histopathology conﬁrmed the presence of tumor deposits in this area
(i). The lower rows represent a patient with a tumor-free surgical margin Fig. 5 k–t. Deeper sectioning of the FFPE block (q, r) was performed to investigate
the probable cause of the high ﬂuorescent area within the green dashed line (t). u, v Arrow depicts the surgical positive margin. Dashed white/black circle
indicates the area with the highest ﬂuorescence signal intensities. The asterisk represents the position of the extra suture mark. The gray box represents
the origin of the FFPE block in the fresh tissue slice. The dashed white/black line delineates tumor tissue. The dashed green line delineates collagen tissue
with normal parenchyma. Scale bars represent 1 cm
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within the analytical workﬂow. In seven out of eight patients,
tumor-positive resection margins were detected during
ﬂuorescence-guided surgery that were missed by intraoperative
assessment of surgical margins using standard visual inspection
and palpation. Because the tumor-involved surgical margins
could be detected intraoperatively in real time, these patients
might have avoided additional surgery or therapy. This indicates
the clinical value of intraoperative molecular ﬂuorescence ima-
ging in breast cancer patients and supports a paradigm shift in the
future treatment of breast-conserving surgery, however the long-
term impact of molecular ﬂuorescence imaging on relevant
clinical endpoints needs to be conﬁrmed in next phase clinical
trials, for instance the reduction in positive-margin rates
(Table 2).
Besides guiding intraoperative decision making, ﬂuorescence
imaging could also have a signiﬁcant impact on the workﬂow of
pathological analysis. In current clinical practice, histological
analysis of the complete surgical specimen is not possible due to
practical and logistical constraints. Moreover, sampling tissue for
histological analyses is based only on gross examination by visual
inspection and palpation of the fresh serially sliced specimen by
the attending pathologist; therefore, tumor-involved margins may
not be included in total in the FFPE tissue blocks, thus causing a
sampling error. Macroscopic ﬂuorescence imaging of the fresh
surgical specimen and the fresh tissue slices can provide the
pathologist with a red-ﬂag technique that precisely outlines tumor
tissue (i.e., image-guided pathology). This could optimize current
tissue sampling procedures and prevent sampling errors.
Importantly, in our study we conﬁrmed the cross-correlation of
ﬂuorescence-guided surgery with ﬁnal histopathology, considered
the gold standard. This is crucial for the further implementation
of ﬂuorescence image-guided histopathology.
Additionally, the current intraoperative clinical workﬂow is
constrained by a considerable time lag between the clinical
decision making of the surgeon (intraoperative evaluation, min-
utes-hour) and the determination of presence or absence of a
tumor-positive margin by the pathologist (post-operative eva-
luation, days-week). We propose that image-guided pathology
might bridge the gap between the surgical theatre and the
pathology laboratory for reliable margin assessment, as ﬂuores-
cence images of the specimen can be provided in real-time and
simultaneously to both disciplines, which will lead to a dynamic
interaction between in vivo intraoperative imaging and ex vivo
macroscopic imaging of the surgical specimen. This could
improve surgical outcome when it counts the most—during
surgery—with a direct impact on clinical decision making.
Although this study was designed as a dose escalation study, we
cannot draw deﬁnitive conclusions on the optimal tracer dose for
clinical decision making. This is due to the relatively small
number of patients included in the lowest and highest dosing
groups, leading to an unequal distribution of patients with tumor-
involved surgical margins in the four dose groups. While the
current study already showed the value on detecting tumor-
involved surgical margins by an increased detection rate of 88%,
sufﬁcient data points are needed to determine the deﬁnitive
diagnostic accuracy and to derive the optimal threshold of
ﬂuorescence intensities for intraoperative decision making.
Assuming that 15 patients with a tumor-involved surgical margin
is sufﬁcient per dose group, a total of 45–75 patients per dose
group might be needed, given the 20–30% tumor-involved sur-
gical margin rate in breast cancer surgery known from this study
and from literature.
We observed a larger variation of ﬂuorescence intensities in
tumor tissue between patients in the 25 and 50mg dose groups
compared to 4.5 and 10 mg dose groups. Factors that might
indicate protein saturation in tumors in doses from 25mg on
might be tumor size, tumor grade, and tumor type. Data derived
from clinical studies evaluating cetuximab-800CW targeting
Endothelial Growth Factor Receptor (EGFR) in head- and neck
cancer, we learned protein saturation occurs in higher dose
groups as it has shown decreasing TBRs with higher doses18.
Based on literature data, it is known that higher VEGF mRNA
expression values are associated with higher grade tumors, but
also with negative ER/PR status, and positive HER2 status19.
Most likely, the small sample size within our study limits deﬁ-
nitive conclusions about correlation of tracer uptake with clin-
icopathological parameters. Therefore, the correlation of
ﬂuorescence intensity and clinicopathological parameters needs
to be investigated in a next phase clinical trial.
In ﬁve patients, the tumor-to-parenchyma ratio in the micro-
segmentation results was below 1, what means that the tumor
MFI was lower than the MFI of the parenchyma tissue. Especially
in the micro-segmentation results it becomes more apparent that
the tumor-to-parenchyma ratio is lower than the TBR, compared
to for example the results of the macro-segmentation analyses of
the fresh tissue slices. Although parenchymal tissue including
collagen showed high tracer uptake, it is to be expected that this
tissue will only attribute relatively to background ﬂuorescence
intensity intraoperatively, which is supported by the fact that in
only one out of these ﬁve patients this resulted in a false positive
cavity signal according to the intraoperative image analyses
(Supplementary Fig. 2d ﬁrst row). Only large areas of par-
enchymal tissue including collagen may inﬂuence the TBR
in vivo, which might be challenging in patients with a tumor
directly behind the nipple and in premenopausal patients with
dense breasts.
We described the analytical platform which is optimized for
800 nm optical agents in particular in terms of instrumentation
adapted to NIR ﬂuorescence imaging (i.e., around the 800 nm
range). Moreover, the analytical workﬂow is generally applicable
for analyses of optical agents with other wavelengths, considering
when a paired detection camera is used that is adapted to the
particular wavelength of interest of the ﬂuorophore.
In conclusion, by implementing a novel analytical workﬂow for
molecular ﬂuorescence imaging we have demonstrated the clin-
ical feasibility of molecular ﬂuorescence-guided surgery using the
ﬂuorescent tracer bevacizumab-800CW in breast-conserving
surgery. A larger study including clinical endpoints is needed to
conﬁrm the optimal dose of bevacizumab-800CW to be used in a
next phase randomized clinical trial. Furthermore, our analytical
platform could be used in future clinical studies on the clinical
translation and evaluation of other tumor-targeted ﬂuorescent
tracers for molecular ﬂuorescence-guided surgery, and also in
different tumor types. Therefore, this analytical platform might
Table 2 Contingency table of molecular ﬂuorescence-guided surgery in breast cancer patients
Surgical margin tumor positive Surgical margin tumor negative Total
Fluorescence signals in cavity positive 7 2 9
Fluorescence signals in cavity negative 1 16 17
Total 8 18 26
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serve as a standard for data collection and ﬂuorescence image
analyses in trials investigating molecular ﬂuorescence imaging
(Supplementary Fig. 5).
Methods
Bevacizumab-800CW synthesis. Clinical grade bevacizumab-800CW was pro-
duced in the good manufacturing practice (GMP) facility of the UMCG by con-
jugating bevacizumab (Roche AG) and IRDye-800CW-NHS (LI-COR Biosciences
Inc) under regulated conditions16. The average conjugation molecule ratio of
bevacizumab (molecular weight: 149 KDa) to IRDye-800CW-NHS (molecular
weight: 1.166 KDa) was 1:2, generating the conjugate bevacizumab-800CW with a
total molecular weight of 151.3 KDa. Vials containing 6.0 mg bevacizumab-800CW
dissolved in 0.9% sodium chloride (NaCl) solution were used to prepare the
infusions in a concentration of 1 mgml−1. After release of the ﬁnal product by the
certiﬁed qualiﬁed person at the UMCG GMP facility, the tracer was intravenously
administered to the subjects.
Gel electrophoresis. Tumor lysates of a patient from the 10 mg group, and one
patient from the 25 mg group were analyzed by sodium dodecyl sulfate poly-
acrylamidegel electrophoresis (SDS-PAGE), to ensure the complete compound
bevacizumab-IRDye800CW was present in the primary breast tumor. Additional, a
lysate of normal tissue was analyzed. Results were compared with labeled and
unlabeled clinically used bevacizumab. The gel was scanned with the Odyssey
ﬂatbed scanner at the 800 nm channel.
Clinical trial design. The dose-ﬁnding study was performed in two centers in 26
patients with proven primary breast cancer scheduled for surgery. This study was
approved by the Institutional Review Board of the University Medical Center
Groningen (UMCG, Groningen, the Netherlands) for conduction of the study in
both the UMCG and in the Martini Hospital (MZH; Groningen, the Netherlands),
a peripheral training hospital being representative for the general population of
breast cancer patient operated on in The Netherlands. The study was conducted
according to the principles of the Declaration of Helsinki and according to the
Dutch Act on Medical Research involving Human Subjects (WMO). Patients with
proven primary breast cancer scheduled for surgery were recruited during multi-
disciplinary breast cancer meetings in either the UMCG or Martini Hospital. Eli-
gible patients were given orally and written information about the study and the
option to participate. All human participants gave written informed consent before
the start of the study procedures. An independent data safety monitoring board
was appointed prior to the inclusion of the ﬁrst patient to evaluate safety measures.
Serious adverse events, if present, were immediately reported to the investigational
review board of the UMCG, the data safety monitoring board, and the Dutch
central committee on research involving human subjects (CCMO). The trial was
registered at www.ClinicalTrials.gov (identiﬁer: NCT02583568).
We designed an adapted 4 × 3 dose-ﬁnding study design, adhering to the FDA
guidelines (Guidance for Industry, Developing Medical Imaging Drug and
Biological Products, Part 2 Clinical Indications). This study consisted of two parts.
In part I, four ascending ﬂat doses of 4.5 mg (4.5 mL), 10 mg (10 mL), 25 mg (25
mL), and 50 mg (50 mL) bevacizumab-800CW were intravenously administered to
three patients each. The dosing scheme that was used in the trial is based on the
deﬁnition of microdosing. We wanted to be sure to stay more than three times
below the therapeutic dose in the highest dose group. For patients who are on
combination therapy with bevacizumab to treat their cancer, it is commonly
accepted that the patient can safely undergo surgery 6 weeks after termination of
the bevacizumab therapy: i.e., at this time the anti-angiogenetic effects have
diminished sufﬁciently to assure there is no increased risk of bleeding or post-
operative complications related to bevacizumab. The plasma levels of bevacizumab
after a wash out period of 6 weeks equals the peak plasma levels after a 160 mg IV
dose (as calculated by the Hospital Pharmacy and the department of Medical
Oncology at the UMCG). Since the Bevacizumab-800CW will be used in surgery,
the dose should stay below 160 mg total injected dose, for which the maximum ﬂat
dose of 50 mg in this clinical trial stays signiﬁcantly below. We administered a ﬂat
dose per cohort, the dose was not adjusted for body weight or body surface area.
In part II, the most optimal performing dose group and one de-escalating dose
were chosen on the basis of TBR to be expanded to a total of 10 subjects in each
group in order to obtain a sufﬁcient number of data points to decide on the optimal
dose for a future phase III clinical study (Supplementary Fig. 1). Patients received a
single dose of one of the 4 dosages bevacizumab-800CW three days prior to
surgery. The lower doses of 4.5 and 10 mg were injected by slow bolus injection,
and for 25 and 50 mg an infusion pump was used (infusion speed: 150 mL per
hour). After injection, the infusion line was ﬂushed with 5 mL 0.9% NaCl.
Safety measurements. Vital signs were measured prior to tracer injection,
immediately after tracer injection and one-hour post-injection. Before tracer
administration blood levels of potassium, magnesium, and calcium was measured.
A pregnancy test was performed if patients were premenopausal. A standard 12-
lead electrocardiogram (ECG) was made before tracer injection and one-hour post-
injection. The following parameters were reported: heart rate, QT- and QTc time.
QT correction for heart rate was done using the Bazett formula. In the ﬁrst 12
patients of the current study, and in 17 patients in the clinical trial NCT02113202
no QTc prolonging was observed when patients received 4,5, 10, 25, and 50 mg
bevacizumab-800CW, therefore the local investigational review board and the data
safety monitoring board agreed to terminate ECG measurements in Part II of this
trial. Patients were asked for signs and symptoms before tracer injection, during
one-hour observation period after tracer injection, and prior to surgery. After
surgery, a post-surgery follow-up assessment was performed within two weeks. At
this visit wound healing and adverse events were monitored.
Standard surgical procedure. Patients underwent either a lumpectomy (n= 24)
or a mastectomy (n= 2) with or without a sentinel lymph node biopsy or axillary
lymph node dissection, according to institutional standard of care procedures and
guidelines. Tumor localization was done with either manual palpation, wire gui-
dance, or using an iodine seed according to standard clinical care. Sentinel lymph
node mapping was done using 99mTechnetium using a gamma-probe, 99mTech-
netium was injected intratumorally one day before surgery conform standard
clinical care.
Based on our previous experience in ﬂuorescence imaging we adapted the
standard of care minimally. We used blue non-ﬂuorescent sterile covers in this
study and avoided blue dye injection for sentinel lymph node mapping, as green
color sterile covers and patent blue interfere with ﬂuorescence signals.
Intraoperative ﬂuorescence imaging device. We used a ﬂuorescence camera
system dedicated to detect IRDye-800CW-NHS (SurgVision BV ‘t Harde, The
Netherlands). The system was conﬁgured with two LED lights for 800 nm illu-
mination and one LED light for white light illumination. Real-time color and NIR
ﬂuorescence images and videos were acquired simultaneously with custom software
at video rate. Fluorescence was detected using a highly sensitive electron-
multiplying charge-coupled device (EMCCD) imaging sensor. In the color-NIR
overlay images, 800 nm images were pseudo colored green. The working distance
of the imaging system was 20 cm above the surgical ﬁeld with a ﬁeld of view of 15
cm × 15 cm, and a spatial resolution of ~2-line pairs per millimeter. For each
experiment, settings were held constant on 50 ms exposure time and 300 gain; if
ﬂuorescence oversaturation occurred in higher dose groups we lowered the gain to
30 or 3 accordingly. Images and videos were recorded and stored in raw Flexible
Image Transport System (FITS) format.
Before and after each surgical procedure the intraoperative camera system was
calibrated using a calibration device (CalibrationDisk, SurgVision BV, The
Netherlands). The device consists of a disk with round windows that can hold 8
clear polypropylene tubes of 0.65 ml (Catalog #15160, Sorenson, BioScience, Inc,
Murray, U.S.A.) (Supplementary Fig. 4). The tubes were ﬁlled with 2% intralipid
and two-fold increasing concentrations of bevacizumab-800CW from 1:6400 till
1:100 including one tube without tracer. The CalibrationDisk was used to test the
system prior to and after surgery, whether low and high ﬂuorescent signals could be
detected from dilutional series and whether the system was functioning
appropriately.
Intraoperative imaging procedures. This clinical trial was not designed to alter
the standard of care, and surgeons were not allowed to excise additional tissue
based on ﬂuorescence signals intraoperatively detected. Therefore, intraoperative
ﬂuorescence imaging took place at two predeﬁned time points during the surgical
procedure: (1) after skin incision the tumor area was imaged just before excision of
the complete surgical specimen, and (2) after removal of the specimen the surgical
cavity was inspected for remaining ﬂuorescence signals. During imaging, the sur-
geon was looking at a stand-alone computer monitor connected to the intrao-
perative imaging system. During the imaging procedures the ambient light of the
surgical theater is switched off in order to prevent interaction of the ambient light
with the ﬂuorescence signals and also to have the highest sensitivity for detection of
ﬂuorescent signals during surgery, because the surgical ﬁeld is also illuminated by
the white light of the camera system, the surgeon can still see in real life what
occurs in the surgical ﬁeld. This set up did not inﬂuence the standard of care.
Specimen handling. After excision of the surgical specimen orientation marks
were placed according to standard clinical care. A short-short suture marked the
posterior side of the specimen and a long-long suture marked the nipple side of the
specimen.
Fluorescence imaging systems for ex vivo imaging. The light-tight macroscopic
ﬂuorescence imaging device (SurgVision BV, The Netherlands) is designed for
ex vivo ﬂuorescence imaging and consists of an object table and a Complementary
Metal Oxide Semiconductor (CMOS) camera which are fully shielded by a light-
shielded box in order to create a dark imaging environment. The distance between
the object table and the CMOS camera is ﬁxed with a ﬁeld of view of 10 cm by 10
cm. For each experiment, settings were held constant with a ﬂuorescence exposure
time of eight seconds. In two cases the light-tight macroscopic ﬂuorescence ima-
ging device did malfunction and the intraoperative imaging system was used for
imaging of the fresh surgical specimen and fresh tissue slices in a dark
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environment. Before each experiment started, the ex vivo imaging device was
calibrated with the same calibration device as previously described.
The multi-diameter single-ﬁber reﬂectance/single-ﬁber ﬂuorescence (MDSFR/
SFF) spectroscopy system calibrates scattering signals in the reﬂectance spectra and
provides a quantitative measurement of the NIR signal emitting from the
bevacizumab-800CW tracer20. The MDSFR/SFF spectroscopy device was calibrated
internally using a 6.6% intralipid phantom.
We used the Odyssey® CLX ﬂuorescence ﬂatbed scanning system (LI-COR
Biosciences Inc. Lincoln, Nebraska) for detecting ﬂuorescence in FFPE blocks and
10-µm-thick sections.
An inverted microscope (DMI6000B, Leica Biosystems GmbH, Wetzlar,
Germany) was used for ﬂuorescence microscopy with a pixel size 6.45 µm, a ﬁeld of
view: 120 × 120 mm. To optimize NIR visualization, the microscope was equipped
with additional accessories, including a NIR LED light source ranging up to 900 nm
(X-Cite 200DC, Excelitas Technologies, Waltham, MA, USA), an NIR ﬁlter set
(microscope two band- pass ﬁlters 850–890 m–2p and a long-pass emission ﬁlter
HQ800795LP; Chroma Technology Corp, Bellows Falls, VT, USA), a monochrome
DFC365 FX ﬂuorescence camera (1·4 M Pixel CCD, Leica Biosystems GmbH), and
LAS-X software (Leica Biosystems GmbH). We used an acquisition time of 10 s for
images of the 800 nm channel.
Imaging procedures of the fresh surgical specimen. All the procedures took
place in a dark environment as much as possible, to prevent photobleaching of the
tracer. The fresh surgical specimen is handled conforming current clinical practice
(see also page 18). Upon arrival at the pathology department, the fresh surgical
specimen was imaged in the light-tight macroscopic ﬂuorescence imaging device
on every six sides corresponding to the in vivo situation, which are anterior,
posterior, medial, lateral, cranial, and caudal sides. The specimen was imaged on
average of 60 min after removal of the tissue, image duration was 6 min per spe-
cimen. After freezing the whole fresh specimen in a −20 °C freezer for 15 min, the
whole specimen was marked with black and blue ink, because these are non-
ﬂuorescent in the NIR range and do not interfere with the bevacizumab-800CW
tracer signal. The limitation on the use of ink color did not affect the standard of
care pathology practices in both institutions participating in the study. Subse-
quently, the fresh surgical specimen was serially sliced into 0.5-cm-thick fresh
tissue slices. A photograph of all fresh tissue slices was made. Before formalin
ﬁxation, all fresh tissue slices were imaged on both sides in the light-tight mac-
roscopic ﬂuorescence imaging system. The fresh tissue slices were imaged on
average of 180 min after removal of the tissue, image duration was 15 min for both
sides of all fresh tissue slices of a patient. Furthermore, one fresh tissue slice per
patient which clearly contained tumor based on gross examination, was used for
MDSFR/SFF spectroscopy analysis. We placed the MDSFR/SFF spectroscopy probe
on top of tumor tissue and normal tissue for quantitative measurements of NIR
ﬂuorescence. Per patient three spots were measured of both tissue types, per spot
three measurements were done. Thereafter, the fresh tissue slices were ﬁxed in
formalin overnight. The next day, the pathologist macroscopically examined the
specimen and selected tissue samples that were embedded in parafﬁn blocks and
processed further for histological analyses. Tissue was embedded conforming
standard clinical practice; in our institution the pathologist decides, based on visual
inspection and palpation and gross examination, which tissue areas need to be
embedded in FFPE blocks. This study was performed without altering the standard
of care and therefore we did not inﬂuence the pathologist on selection of which
tissue to be embedded in FFPE blocks. After the pathologist was ﬁnished with
macroscopic selection, additional tissue samples were embedded if high ﬂuores-
cence signals were detected in images of the fresh tissue slices in regions that
would not have been embedded for standard clinical care. The tissue cassette
numbers were marked on a printed photograph of all fresh tissue slices, to enable
direct correlation between ﬂuorescence signals in fresh tissue slice images and
histology.
Imaging procedures of formalin-ﬁxed tissue. All FFPE blocks of all patients were
requested from the pathological department and were scanned with the Odyssey®
CLX ﬂuorescence ﬂatbed scanning system. All FFPE blocks were scanned with the
same imaging settings (wavelength: 800 nm, resolution 21 µm, quality: highest,
intensity: 5).
We made 10-µm-thick tissue sections of all FFPE blocks of all patients. The 10-
µm-thick sections were deparafﬁnized in xylene for two times ﬁve minutes each. It
has been shown in an earlier clinical study executed by our group that dehydration
or deparafﬁnation in xylene steps has no effect on the presence of the compound,
and no effect on the measurements of the ﬂuorescent signals (unpublished data
from clinical trial: Lamberts et al.)7. Thereafter, we left the slides to dry in the air in
a dark environment. When dry, we imaged the slides using the Odyssey® CLX
ﬂuorescence ﬂatbed scanning system (LI-COR Biosciences Inc.) with the same
imaging settings to all slides (wavelength: 800 nm; resolution: 21 µm, quality:
highest, intensity: 8). After scanning the tissue slides, we directly performed
hematoxylin/eosin (H/E) staining to enable direct correlation between ﬂuorescence
signal and histology on the same slide. H/E slides were digitalized using a digital
slide scanner (Hamamatsu, Japan).
Fluorescence microscopy. We made additional 4-µm-thick sections for micro-
scopic assessment of the NIR signal derived from bevacizumab-800CW in order to
evaluate the tracer distribution at a cellular level. The cell nuclei were counter-
stained with Hoechst (33258, Invitrogen, Waltham, MA, USA) The sections were
mounted under a cover glass in modiﬁed Kaiser’s glycerin.
Macro-segmentation of the fresh tissue slices. We used images of the fresh
tissue slices of all 26 patients to determine the TBR per patient. TBR was deﬁned as
the MFI measured in breast cancer tissue divided by the MFI in surrounding
healthy tissue at macroscopic level. We used images of the fresh tissue slices as a
representative model for the in vivo situation for the macro-segmentation analyses
for calculating the TBR. Fresh tissue represents the in human situation best because
this tissue is not yet ﬁxed with formalin or embedded in parafﬁn and the conditions
of imaging are the most optimally standardized. The tumors within the slices are all
on the surface without overlaying tissue, the distance from stage to camera is equal
in all patients, and no ambient light is inﬂuencing the ﬂuorescent signals. All raw
(FITS-format) ﬂuorescence images of fresh tissue slices that contained tumor tissue
were imported in ImageJ (Fiji, version 1.0). ROIs were deﬁned using the analytical
workﬂow, because we could exactly correlate the origin of all FFPE blocks from the
fresh tissue slice. As we know this origin we used the corresponding histological
slice to conﬁrm tumor areas and background areas of normal tissue in the fresh
tissue slices. ROIs of the total tumor tissue area, as well as the total background
tissue per fresh tissue slice are deﬁned by MK and drawn manually. Mean ﬂuor-
escence intensities (MFI, arbitrary units) of all fresh tissue slices containing tumor
tissue were measured per ROI and averaged per tissue type per patient, resulting in
a MFI of tumor tissue and MFI of background tissue per patient. The TBR was
calculated for each patient by dividing the MFI of tumor tissue by the MFI of
surrounding healthy tissue. After each dose group was ﬁnished, MFI of tumor
tissue, MFI of healthy surrounding tissue and TBR for each patient were plotted in
graphs (GraphPad Prism, version 7.0b). Derived from previous studies executed
with 800CW labeled cetuximab18, it was anticipated that a plateauing of TBRs level
might occur with increasing doses and therefore further increasing the dose is of no
further clinical need in terms of imaging TBRs. Once the TBR reached a plateau, it
was considered as an indicator that the optimal dose was reached.
MDSFR/SFF spectroscopy. The MDSFR/SFF spectroscopy gains two reﬂectance
spectra via two different optical ﬁbers and one raw ﬂuorescence spectrum. The
scattering and absorption coefﬁcients were determined from the reﬂectance spec-
tra, which were used to determine the intrinsic ﬂuorescence (Q.μfa,x) of
bevacizumab-800CW by correcting the ﬂuorescence spectrum for the calculated
tissue optical properties20. The intrinsic ﬂuorescence Q.μfa,x is deﬁned as the
product of the quantum efﬁciency across the emission spectrum, Q[-], where Q is
the ﬂuorescence quantum yield of IRDye-800CW and μaf [mm−1] is the tracer
absorption coefﬁcient at the excitation wavelength. MDSFR/SFF spectroscopy was
performed in UMCG patients only; since the system was not available in the MZH
center. In one patient, the measurements failed because the device malfunctioned.
Micro-segmentation for assessment of the biodistribution. We performed
micro-segmentation of 10-µm-thick FFPE sections to determine biodistribution of
bevacizumab-800CW in human breast tissue. In summary, after ﬂuorescence
scanning and HE staining of 10-µm-thick tissue sections, an experienced breast
cancer pathologist (BVDV) reviewed the histology of all slides. Different tissue
components (e.g., invasive carcinoma, carcinoma in situ, benign proliferative
lesions, reactive lesions, and healthy parenchymal tissue including collagen and fat)
were identiﬁed and delineated manually on the digitalized HE slides. Delineated
tissue components were exported as ROIs using Photoshop (Adobe Creative Cloud
2017). Fluorescence images of the 10-µm-thick sections as well as the ROIs con-
taining different tissue components were imported in ImageJ (Fiji, version 1.0). Per
ROI a ﬂuorescence measurement was performed resulting in an MFI per tissue
component per slide. Per patient a mean MFI was calculated per tissue component
and plotted in a graph (Graphpad Prism, version 7.0b).
The potential clinical value of ﬂuorescence-guided surgery. Clinicopathological
analyses of specimens were reported conforming standard clinical care, which
contained at least macroscopical description, microscopical description including
tumor type, modiﬁed Bloom-Richardson grade, surgical margins, and receptor
status. If present, microscopic description of carcinoma in situ was reported
accordingly.
All intraoperative ﬂuorescence images and videos of the surgical cavity of all 26
patients were reviewed by MK, a trained and experienced technical team member
and blinded for histopathology. The analyses of all the images took place after the
study was ﬁnished and all data were collected. Patients were divided on having
presence or absence of ﬂuorescence signals in the surgical cavity. Presence of
ﬂuorescence signals was deﬁned as clear ﬂuorescence signals that have higher
ﬂuorescence intensities compared to lower ﬂuorescence intensities from
background tissue, what means that high ﬂuorescence signals could be easily
delineated from lower background signals. To correlate ﬂuorescence signals with
having a tumor-involved surgical margin, a contingency table was analyzed. The
surgical margin was considered to be positive if ink was present on invasive cancer
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or carcinoma in situ, according to the most recent SSO-ASCO guidelines on breast
cancer9,21.
Statistical analysis. MFI was deﬁned as total counts per ROI pixel area in tumor
and background normal tissues. Data were tested for Gaussian distribution; none of
the data was normally distributed. Fluorescence signal intensities between four
different dose groups were compared using Kruskal–Wallis test with a Dunn’s
multiple comparison test as post hoc analyses. Fluorescence signal intensities
between different tissue types within one dose group was analyzed with the
Mann–Whitney U-test. Data are presented as boxplots with bars depicting mini-
mum and maximum values, or median values were indicated with lines. Correla-
tion between ﬂuorescence intensity and clinicopathological parameters was tested
with Spearman’s correlation test. A two-sided P value of less than 0.05 was con-
sidered signiﬁcant. We used GraphPad Prism, version 7.0b Software for statistical
analysis.
Data availability. The datasets generated during and/or analysed during the
current study are available from the corresponding author on reasonable request.
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